Background. Intravenous iron management is common in the haemodialysis population. However, the safest dosing strategy remains uncertain, in terms of the risk of hospitalization and mortality. We aimed to determine the effects of cumulative monthly iron doses on mortality and hospitalization. Methods. This multicentre observational retrospective propensity-matched score study included 1679 incident haemodialysis patients. We measured baseline demographic variables, haemodialysis clinical parameters and laboratory analytical values. We compared outcomes among quartiles of cumulative iron dose (mg/kg/month). We implemented propensity-score matching (PSM) to reduce confounding due to indication. In the PSM cohort (330 patients), we compared outcomes between groups that received cumulative iron doses above and below 5.66 mg/kg/month. Results. Kaplan-Meier analyses showed that the high iron dose group had significantly worse survival than the low iron dose group. A univariate analysis indicated that the monthly iron dose could significantly predict mortality. However, a multivariate regression did not confirm that finding. The multivariate regression analysis revealed that iron doses >5.58 mg/kg/month were not associated with elevated mortality risk, but they were associated with elevated risks of all-cause and cardiovascular-related hospitalizations. These results were ratified in the PSM population. Conclusions. Intravenous iron administration is advisable for maintaining haemoglobin levels in patients that receive haemodialysis. Our data suggested that large monthly iron doses, adjusted for body weight, were associated with more hospitalizations, but not with mortality or infection-related hospitalizations.
I N T R O D U C T I O N
Anaemia is one of the most common medical complications in patients with chronic kidney disease (CKD), and it is strongly associated with outcome [1, 2] . Prior to the introduction of recombinant erythropoiesis-stimulating agents (ESAs), blood transfusions were required to treat anaemia in patients with CKD stage 5D (CKD5D) that required haemodialysis. Currently, haemoglobin levels can be optimized by administering ESAs combined with intravenous iron (FeIV) [3] . However, many patients with CKD5D remain in negative iron balance, due to reduced dietary intake, reduced gut absorption and iron losses related to haemodialysis or bleeding [4] [5] [6] . An additional factor associated with iron metabolism is the ferritin and transferrin saturation index (TSAT), which summarizes the classical clinical parameters that typically guide physicians in prescribing FeIV to prevent anaemia [7] ; these parameters have shown shortcomings in assessing iron status [8] [9] [10] . Haemoglobin control reportedly improves with low ESA doses and elevated FeIV prescriptions; however, high FeIV doses are reportedly associated with increased oxidative stress, cardiovascular events, vascular calcifications, infections and liver iron accumulation [11] [12] [13] . It remains unclear whether these toxic effects associated with cumulative iron doses depend on the total iron dose delivered or the dose infused within a certain exposure time [14, 15] .
In this study, we analysed data from a cohort of incident haemodialysis patients. We aimed to determine how mortality and hospitalization risks were related to the cumulative monthly iron dose (adjusted for body weight) delivered during the follow-up period.
M A T E R I A L S A N D M E T H O D S
We evaluated all adult incident haemodialysis patients receiving renal replacement therapy <90 days before study enrollment and treatment with FeIV (starting within the first 3 months of haemodialysis initiation) at any of the Spanish Fresenius Medical Care (FMC) clinics, between July 2011 and September 2014 ( Figure 1 ). Exclusion criteria were: a prior history of renal transplantation or peritoneal dialysis or withdrawal from the study within 90 days. Also, vascular access (VA) is a powerful confounding factor related to outcome [16] ; therefore, patients were excluded when the same VA could not be maintained for at least 75% of sessions.
All participants provided signed consent to authorize the use of their information for scientific research. Data were acquired from the FMC EuCliD V R clinical data system [17] . We collected demographic variables, including age, gender, Charlson comorbidity index (CCI) and body mass index (BMI). We retrieved haemodialysis clinical parameters, including: the VA type [central venous catheter (CVC) or native arteriovenous fistula (AVF)], Kt/V, Kt (L) and the effective treatment time (Td, min). We also retrieved laboratory analytical values related to the main study outcome, including: haemoglobin (g/dL), ferritin (mg/L), TSAT (%), erythropoietin resistance index (ERI), C-reactive protein (CRP, mg/L) and albumin (g/L).
For each patient, we calculated the average monthly iron dose per kilogram of body weight (mg/kg/month) accumulated during the follow-up period [14, 15] . The FeIV utilized was either iron sucrose Venofer V R (ViforFMC Renal Pharma, Zurich, Switzerland) or Feriv V R (GES; Las Rozas, Madrid, Spain). FeIV was administered as a bolus injection during the entire exposure period. The weekly ESA dose was also recorded. Due to the heterogeneity in the ESA utilized, the doses were adjusted to international units (IU) and recorded in terms of IU/kg/week, according to the different manufacturers' instructions. ESA and FeIV were administered according to the standard medical practice, based on the recommendations established by the ERBP and KDIGO guidelines for anaemia treatment [18, 19] . These recommendations prescribed ESA and iron administrations as doses aimed to achieve a haemoglobin target of 10-12 g/dL, ferritin levels between 100 mg/L and 800 mg/L and TSAT 20-50%. All haemodialysis sessions were performed with FMC 4008S or 5008 monitors and synthetic Fresenius Polysulfone V R Helixone dialysers of 1.4-1.8 m 2 , in a non-reusable manner. The weekly Td target was 720 min and the dialysis dose target was Kt/V !1.4 per session.
Statistical analysis
All statistical tests were performed with SPSS 23.0. P < 0.05 was considered significant. Variables were compared according to the outcome (living versus dead) with the chi-square test for categorical variables (presented as percentage values), the t-test for normally distributed variables [presented as mean 6 standard deviation (SD)] or the Wilcoxon rank sum test for continuous parameters with non-normal distributions (presented as median and interquartile range). Variables were compared across quartiles of iron dose with the chi-square test for categorical factors and ANOVA for continuous variables. Variables with heavy positive skewness were analysed with the Kruskal-Wallis test. When ANOVA results were significant, the Scheffé post hoc test was performed to identify homogeneous subsets. This study's primary aim was to evaluate whether Fe/kg/ month constituted an independent predictor of mortality. Therefore, the Kaplan-Meier method was used to estimate survival, and survival rates within iron dose quartiles were compared with the log-rank test. The Cox regression model was used to calculate the corresponding hazard ratios (HRs) with a 95% confidence interval (CI) for all-cause mortality; the low iron dose quartile served as the reference.
We used univariate models to explore the linear effects of the continuous variables. The corresponding cut-offs were chosen in a clinically meaningful way, with an effort to create balanced groups, as follows: We also analysed the relationship between the Fe/kg/month and the risk of all-cause hospitalization. We performed univariate and multivariate logistic regression analyses of predictors associated with hospitalization risk, with the sequential method described above for mortality (crude, demographics-adjusted, case-mix-adjusted CRP, case-mix-adjusted albumin and adjusted models). The same strategies were applied to define the relationship between the Fe/kg/month and the risk of multiple hospitalizations during the follow-up period or hospitalizations due to infectious diseases (related to the VA or the cardiovascular condition).
In a preliminary sensitivity analysis, we recalculated the average monthly iron dose accumulated during the follow-up period without taking into account the weight of each patient. We used this new approach to compare mortality and hospitalizations across quartiles of iron doses.
To minimize the bias by indication, we implemented propensity-score matching (PSM). We calculated the propensity score for each patient by modelling the probability of receiving an accumulated Fe/kg/month of either 5.65 mg/kg/month or !5.66 mg/kg/month. This cut-off value was selected based on the mean weight of the entire cohort (70.77 6 14.66 kg). This cut-off value also coincided with the highest iron dose category analysed in the DOPPS study [15] . We constructed logistic regression models and introduced all the predictors used to explore the hospitalization and mortality risks. The derived propensity scores were used to match the groups at a 1:1 ratio with a caliper-matching algorithm. This algorithm fixed the caliper parameter to 0.2 of the pooled SD of the logit of the propensity scores [20] . To evaluate the quality of the pairings, we evaluated the balance in the covariates by calculating the absolute difference between values observed before and after the matching, and then performing bivariate comparisons. The PSM method was performed with an SPSS R-Menu based on R-3.1.1 [21] .
R E S U L T S
Data for 1679 patients were retrieved from 59 FMC units. The full cohort comprised 35.27% women; the average age was 69.31 6 13.04 years, and the average CCI was 5.62 6 1.98.
A descriptive analysis of patients alive versus those deceased at the end of the follow-up period (Table 1) revealed that the deceased group was significantly older, showed more comorbidities and had significantly lower BMIs than the surviving group. The two groups had similar gender distributions. Among the clinical haemodialysis parameters, Kt/V and Kt did not significantly differ between groups. On the other hand, the deceased group showed significantly higher CVC use and shorter Tds than the surviving group. Among the analysed laboratory values, the deceased group showed significantly lower haemoglobin, TSAT and albumin, and significantly higher ferritin, ERI and CRP than the surviving group. Finally, the ESA dose and the Fe/ kg/month were significantly higher than in the surviving group.
To analyse the main objective, the patients were grouped into quartiles of Fe/kg/month. We compared demographic features, haemodialysis parameters and laboratory analytical values across quartiles (Table 2) . Among the demographic variables, age and CCI were similar across quartiles. However, quartiles with higher Fe/kg/month values included higher percentages of women than the other quartiles. Additionally, the last two quartiles showed significantly lower BMI values compared with the first two quartiles (Supplementary data, Figure S1 ).
The comparisons of different clinical haemodialysis parameters across quartiles revealed that higher Fe/kg/month quartiles had higher CVC percentages. Moreover, Kt/V and Td differed significantly across quartiles, but not the dialysis dose measured as Kt ( Table 2 ). The corresponding post hoc analysis revealed that patients who received higher levels of Fe/kg/month showed statistically better Kt/V, even though the highest quartile had a significantly shorter Td (Supplementary data, Figure S1 ). This finding was consistent with the lower BMI value recorded for this quartile. Finally, ESA administration was higher in the higher Fe/kg/month quartiles (P < 0.001; Table 2 , Supplementary data, Figure S1 ).
ANOVA results for the analysed laboratory parameters (Table 2 ) revealed progressive and significant decreases in haemoglobin, TSAT and albumin levels across the different quartiles (Supplementary data, Figure S1 ). Moreover, the inflammatory process (CRP) and ferritin levels increased progressively and significantly in correspondence with increasing ESA doses.
Survival analysis
The mean follow-up was 17.79 6 6.45 months. A total of 182 deaths occurred during the observation period. The main causes 
of death were cardiovascular diseases (41.76%), sudden death (12.09%), infectious diseases (10.99%), gastrointestinal diseases (9.89%), tumours (5.49%) and other (19.78%). A total of 312 patients withdrew from the study during the follow-up. The main reasons were kidney transplantation (n ¼ 167), change of haemodialysis unit (n ¼ 125) or other reasons (n ¼ 20). All these patients were properly censored at the time of termination. In the full cohort, the average survival time was 32.30 months (95% CI: 31.81-32.80 months). Kaplan-Meier analyses of survival across quartiles showed that the higher Fe/ kg/month quartiles had significantly lower survival rates than the lower Fe/kg/month quartiles (log-rank test: 43.829; P <0.001; Figure 2 ). The univariate Cox regression analysis suggested that the Fe/kg/month could predict mortality (Table 3) . However, the corresponding multivariate Cox models, which included laboratory parameters, did not show that Fe/kg/month was an independent predictor of mortality (HR-adjusted model, Q4 ¼ 1.343; 95% CI: 0.810-2.225; P ¼ 0.253; Figure 3 ).
Hospitalization
Among the study participants, 998 (59.44%) had a total of 2437 hospital admissions during the follow-up and 33.77% had multiple hospital admissions during the follow-up. The main causes of hospital admissions were infectious diseases (23.26%), cardiovascular diseases (23.18%) and issues related to the VA (16.43%). Figure  4) . However, the Fe/kg/month value could not independently predict multiple hospital admissions (crude, OR Q4 ¼ 1.310; 95% CI: 0.949-1.780; P ¼ 0.084), hospital admissions related to 
Sensitivity analysis
In routine clinical practice, body weight is not always considered when FeIV is prescribed by the nephrologist. Therefore, we replicated the analysis without considering body weight in the calculations. Compared with the demographic analysis with body weight included (Table 2), the demographics of FeIV (mg/month) (Supplementary data, Table S1 ) were not significantly different across quartiles. In contrast, the laboratory analytical values remained significantly different across quartiles. When body weight was neglected, the survival profiles across quartiles were significantly worse among patients in the higher Fe/month quartile (log-rank test ¼ 19.67; P < 0.001; Supplementary data, Figure S2 ), consistent with the previous analyses. The univariate Cox regression analysis suggested that Fe/month could predict mortality (adjusted model, HR Q4 ¼2.349; 95% CI: 1.532-3.6; P < 0.001), but the multivariate Cox models that included laboratory parameters did not confirm that finding (adjusted model, HR Q4 ¼ 1.194; 95% CI: 0.750-1.190; P ¼ 0.456). However, the highest Fe/month quartile was a significant predictor of hospitalization risk (crude, OR Q4 ¼ 1.483; 95% CI: 1.116-1.194; P ¼ 0.006). Finally, the multivariate logistic regression analysis revealed that Fe levels >371.42 mg/month constituted an independent predictor of all-cause hospitalization (adjusted model, OR Q4 ¼ 1.346; 95% CI: 1.027-2.096; P ¼ 0.035).
Although our adjusted regression models included all the variables we collected that might influence mortality and hospitalization, we could not exclude a reverse-causality phenomenon. Moreover, the bias of indication is a major concern in determining an appropriate iron dosing strategy. To address these phenomena, we implemented the PSM method. Baseline characteristics of the cohort before and after PSM are shown in Table 5 . After the resulting balanced population was properly assessed, the adjusted cohort was used to study survival and hospitalization risks. The PSM-adjusted patient cohort confirmed that Fe/kg/month could not independently predict mortality ( Figure 5 ). In contrast, the logistic regression estimations of hospitalization risks confirmed the finding that Fe/kg/month and ESA dose (IU/kg/month); and adjusted model: final model, including both albumin and CRP. The probability that each ratio is significantly different from its reference value is indicated by a symbol near the ratio: # P < 0.001; *P < 0.05; no symbol indicates no significant difference. 
was an independent predictor of all-cause hospitalization and cardiovascular-related hospitalization (Table 6 ).
D I S C U S S I O N
In this multicentre observational study, we examined the comparative safety of FeIV supplementation, based on morbidity and mortality, in a cohort of incident haemodialysis patients. Our data suggested that, although the higher Fe/kg/month quartiles showed worse survival than the lower quartiles, larger iron doses infused over time were not associated with mortality after adjusting for the potential confounding factors analysed. On the other hand, compared with smaller doses, FeIV doses higher than 5.57 mg/kg/month were associated with higher risks of all-cause hospitalization and cardiovascular-related hospitalization ( Figures 2-4 , Tables 3 and 4 ). The outcomes across FeIV quartiles were consistent with and without including body weight in the calculations. All the results were ratified after reducing the indication bias with the PSM-adjusted population ( Figure 5 , Tables 5 and 6 ). In this analysis, administering FeIV at levels >5.65 mg/kg/month or 400 mg/month was not associated with higher mortality, but it was associated with higher risks of all-cause hospitalization and cardiovascular-related hospitalization.
It is widely accepted that FeIV plays an important role in maintaining haemoglobin at target levels in patients undergoing haemodialysis, which consequently improves the quality of life in this population and reduces the ESA requirements [22] [23] [24] . From a mass balance perspective, the total amount of FeIV infused in a patient during haemodialysis reflects the amount of blood loss the patient experienced (dialysis technique, intestine, sampling, etc.). Therefore, the amount of FeIV infused is also related to the comorbidities ; case-mix-adjusted CRP model: demographics-adjusted model with the addition of CRP (mg/L), haemoglobin (g/dL), Kt (L) and ESA dose (IU/kg/month); case-mix-adjusted albumin model: demographics-adjusted model with the addition of albumin (g/dL), haemoglobin (g/dL), Kt (L) and ESA dose (IU/kg/month); and adjusted model: final model, including both albumin and CRP. The probability that each ratio is significantly different from its reference value is indicated by a symbol near the ratio: # P < 0.001; þ P < 0.01; *P < 0.05; no symbol indicates no significant difference.
that lead to blood losses. In this study, we used CCI as a covariate to minimize this confounding factor. However, the international scientific community has not reached a consensus regarding the proper monitoring, safety and dosing strategies for FeIV treatment [3, 10, [25] [26] [27] [28] . Notably, although ferritin and TSAT are the classical clinical parameters that guide physicians in prescribing FeIV for treating anaemia [7] , these parameters have several shortcomings in assessing iron status [8] [9] [10] . The KDIGO Work Group and the ERBP Group recommended the combination of TSAT and ferritin levels for monitoring FeIV administration properly [18, 19] . Theoretically, these parameters reflect the amount of stored iron that is potentially deliverable to the bone marrow for erythropoiesis. However, the TSAT depends on the proximity of the FeIV administration, and when TSAT values are < 20%, ferritin levels are often elevated, which complicates therapeutic decisions [29, 30] . Additionally, transferrin and ferritin are acute-phase proteins; thus, levels change under inflammatory conditions [31] [32] [33] [34] [35] . Moreover, a recent study showed that ferritin levels increased over haemodialysis life time, independent of FeIV treatment [36] . Thus, monitoring FeIV treatment based on ferritin and TSAT is complex.
Another complication in monitoring FeIV is that inflammation is deeply linked to the ESA resistance, which leads to reduced survival and increasingly frequent hospitalization [14, 37] . In the present study, compared with the surviving group, the deceased group had received significantly higher iron doses, with corresponding significant increases in ferritin and TSAT. These patients also displayed significantly higher CRP levels and lower albumin levels, which are both related to inflammation (Table 1) . Therefore, the high FeIV quartiles likely included patients with more pronounced inflammatory conditions, which, in addition to elevated CRP levels, would lead to increased ferritin and TSAT (Table 2) . Moreover, the CVC use would contribute to greater need for FeIV, due to the measures employed to restore its permeability during haemodialysis sessions; therefore, we introduced this covariate in every regression model to minimize its impact. Likewise, the increasing percentage of CVC recorded across FeIV quartiles could contribute to enhancing the CRP levels [38] and to the observed higher mortality (Figure 2 , Tables 2 and 3 ) [39] . These inflammatory parameters could be the main explanation for the differences between the unadjusted and adjusted analyses ( Figure 3 ). Taken together, these results illustrate the problem currently faced by physicians when monitoring FeIV treatment with the gold standard of ferritin and TSAT. Recent international guidelines have suggested that further randomized clinical trials are needed to validate the management of FeIV with hepcidin, the percentage of hypochromic red blood cells or haemoglobin content in reticulocytes; these parameters are independent of chronic inflammation processes in patients who receive haemodialysis [10] .
Several studies have reported conflicting results regarding the association between iron doses and severe outcomes, based on larger databases, like the USRDS or the DOPPS initiative and some meta-analyses [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Our study differed from those studies, because we defined exposure as the patient's average cumulative monthly iron dose (mg/kg/month) over the entire follow-up period. Moreover, we corroborated the classical regression analysis with PSM to minimize the bias by indication.
Remarkable variability exists among different studies in terms of the iron compositions used (e.g. ferric gluconate [30] , ferric chloride [45] , iron dextran [40, 42, 46] and iron sucrose [47] ); sometimes different iron compositions were mixed within a single study [15, 41] . These factors may be crucial in determining associations between FeIV dosing and outcomes, because different iron preparations may have different effects on oxidative stress and chronic inflammation processes that occur in haemodialysis [52] . Moreover, previous studies had various different designs, compared with the present study, in terms of the duration of drug exposure [15, [40] [41] [42] , basing dosage on: patient weight (Supplementary data, Figure S2 ) [14, 15, 40, 41] ; the mode of administration (bolus or maintenance) [43, 44] ; using a reference group in comparing patients with or without FeIV treatment [44, 48] ; and inclusion of prevalent versus incident patients [15, [40] [41] [42] 49] . Overall, these many differences among currently available studies make it difficult to compare results among those studies and with the present study.
Our study did not account for potential prescriptions of oral iron formulations that our population might have received prior to dialysis renal replacement therapy. Moreover, despite the utilization of only one iron compound (iron sucrose) during the entire follow-up period, two different preparations were used for the FeIVs. We performed an additional analysis to compare the two iron preparations used, in an intention-to-treat analysis, where patients were classified according to the iron preparation used in the first months of the study. We constructed a Cox model, adjusted with the same covariates introduced in the regression models. We found similar mortality between groups (HR adjusted ¼ 1.13; 95% CI: 0.84-1.57; P ¼ 0.42). Additionally, we constructed logistic regression models to analyse the hospitalization risks, and found similar risks between groups (OR adjusted ¼ 1.09; 95% CI: 0.96-1.24; P ¼ 0.18).
The present study had several strengths and limitations. The strengths were that we included a large sample size of incident haemodialysis patients treated with the same FeIV composition and received a common drug supplementation strategy to prevent anaemia. However, one limitation was that the study design lacked control groups that were not treated with FeIV or ESA. Another limitation was that we used lower iron doses compared with the previous studies [15] , and this might explain why we found no association between mortality and iron dose in our multivariate analysis. Although we extensively adjusted the different regression models to resolve the reverse causality phenomenon and the indication bias with the PSM method, some residual confounding might have remained. Moreover, a longer observation period might be necessary to evaluate the full impact of FeIV dosing on the outcomes. Further randomized controlled trials, as suggested by the 2016 KDIGO Iron Controversies Report [3] , are urgently needed to clarify the current landscape of FeIV management for patients undergoing haemodialysis. The Proactive IV irOn Therapy for haemodiALysis patients (PIVOTAL) trial [53] , a multicentre open-label randomized controlled trial that plans to include over 2000 incident haemodialysis patients to test the effects of The low iron dose group (defined as 5.65 mg/kg/month) served as reference. CV, cardiovascular.
